Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Screening Pregnant Women for Gestational Diabetes

By LabMedica International staff writers
Posted on 30 Dec 2010
Gestational diabetes mellitus (GDM) is diabetes that occurs during pregnancy. More...
When left untreated it increases the risk of preeclampsia, premature birth, delivery problems requiring cesarean section, and neonatal hypoglycemia.

A study by Quest Diagnostics (Madison, N.J., USA) of 924,873 pregnant women between the ages of 25 and 40 suggested that a large number of women are not being screened according to medical guidelines and they may unknowingly put themselves and their babies at risk for complications from GDM. The study also found that maternal weight was a stronger predictor of gestational diabetes but that ethnicity was even stronger.

Study investigator Jon M. Nakamoto, M.D., Ph.D., medical director, Quest Diagnostics commented, "We were particularly alarmed to find that women who develop the condition [GDM] while pregnant are not being screened for diabetes postpartum, despite overwhelming evidence that they are at great risk for developing diabetes later in life. Considering the diabetes public health crisis, the failure to test these women after their pregnancy is a major concern."

The Quest study is now online and expected to appear in the January 2011 print issue of the journal Obstetrics and Gynecology, the official publication of ACOG.

Current medical guidelines are based in part on results of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) trial, which found that even subtle defects in maternal glucose metabolism during pregnancy led to health problems for both mother and baby.

An estimated 40% to 60% of women with gestational diabetes develop type 2 diabetes within ten years. At present, the American College of Obstetricians and Gynecologists and the American Diabetes Association recommend screening pregnant women for gestational diabetes, and retesting women who do develop pregnancy-related diabetes 6 to 12 weeks after delivering their babies.

Prof. Moshe Hod and Dr. Eran Hadar from the Perinatal Division, Helen Schneider's Hospital for Women, Rabin Medical Center, (Petah-Tiqva, Israel) reviewed the establishment of consensus criteria for the diagnosis of diabetes in pregnancy following the HAPO study. The review appeared in the September 2010 Annals of the New York Academy of Sciences. The authors wrote," A consensus report by the [International Association of Diabetes and Pregnancy Study Groups] IADPSG, based on a vigorous assessment of the HAPO results and other studies, recommended an endorsement of risk-based, internationally accepted criteria for the diagnosis and classification of diabetes in pregnancy."

Related Links:
Quest Diagnostics
American College of Obstetricians and Gynecologists
American Diabetes Association
Rabin Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.